Australia Expands Eligibility for Psychedelic Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Expanded Therapist Eligibility: The TGA's updated framework broadens the eligibility for therapists in psychedelic-assisted therapy, particularly for MDMA and psilocybin, which is expected to significantly enhance treatment accessibility and meet the growing patient demand.
- Diverse Treatment Settings: The new regulations allow treatment to occur in various medically supervised environments rather than just inpatient settings, which is anticipated to improve patient comfort and outcomes, further promoting the adoption of psychedelic therapies.
- Continued Safety Profile: Since December 2025, the TGA has reported no serious adverse events under the Authorized Prescriber scheme, and this clean safety record strongly supports program expansion and enhances public confidence in psychedelic treatments.
- Broadened Reimbursement: Coverage for psychedelic-assisted therapy now spans both public and private payers, including the Department of Veterans' Affairs and the National Disability Insurance Scheme, creating more employment opportunities for trained practitioners while expanding the patient base.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPTH
Wall Street analysts forecast OPTH stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 5.965
Low
Averages
High
Current: 5.965
Low
Averages
High
No data
About OPTH
Optimi Health Corp. is a commercial-stage pharmaceutical company. The Company focuses on manufacturing and distributing good manufacturing practices (GMP) grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, the Company produces validated Methylenedioxymethamphetamine hydrochloride (MDMA) and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. It supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products prescribed to patients in Australia under the country's authorized prescriber scheme and accessible in Canada through the special access program. With its vertically integrated approach, the Company owns and operates two purpose-built 10,000-square-foot licensed production sites in Princeton, British Columbia and holds a Drug Establishment Licence (DEL), as issued by Health Canada.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Australia Broadens Eligibility for Psychedelic Therapy
- Expanded Therapist Eligibility: The TGA's updated framework broadens the eligibility for therapists in psychedelic-assisted therapy, which is expected to significantly enhance treatment capacity and meet the rising patient demand, thereby solidifying Australia's position as a leader in the global psychedelic market.
- Diverse Treatment Settings: The new regulations allow psychedelic therapy to be conducted in various medically supervised environments rather than solely in hospitals, which is anticipated to improve patient comfort and outcomes, further driving the commercialization of psychedelic treatments.
- Sustained Safety Profile: The TGA has confirmed that no serious adverse events have been reported under the Authorized Prescriber scheme since December 2025, and this clean safety record provides strong support for program expansion and enhances public confidence in psychedelic therapies.
- Expanded Reimbursement Coverage: Coverage for psychedelic-assisted therapy now spans both public and private payers, including the Department of Veterans' Affairs and the National Disability Insurance Scheme, creating more employment opportunities for trained practitioners while addressing the growing patient population.
See More
Australia Expands Eligibility for Psychedelic Therapy
- Expanded Therapist Eligibility: The TGA's updated framework broadens the eligibility for therapists in psychedelic-assisted therapy, which is expected to significantly enhance treatment capacity and meet the increasing patient demand, thereby solidifying Australia's leading position in the global psychedelic market.
- Diverse Treatment Settings: The new regulations allow psychedelic therapy to be conducted in various medically supervised environments, breaking the previous requirement for hospital settings, which is anticipated to improve patient comfort and treatment outcomes, promoting a wider range of therapeutic applications.
- Sustained Safety Profile: Since December 2025, the TGA has reported no serious adverse events, indicating a high safety profile for psychedelic treatments under regulated conditions, which provides strong support for further promotion and expansion of therapy programs.
- Expanded Reimbursement Coverage: The reimbursement for psychedelic therapy now spans both public and private payers, enhancing accessibility and affordability of treatments, which is expected to attract more trained practitioners into the market and drive growth in commercial supply.
See More
Australia Expands Eligibility for Psychedelic Therapy
- Expanded Therapist Eligibility: The TGA's updated framework broadens the eligibility for therapists in psychedelic-assisted therapy, particularly for MDMA and psilocybin, which is expected to significantly enhance treatment accessibility and meet the growing patient demand.
- Diverse Treatment Settings: The new regulations allow treatment to occur in various medically supervised environments rather than just inpatient settings, which is anticipated to improve patient comfort and outcomes, further promoting the adoption of psychedelic therapies.
- Continued Safety Profile: Since December 2025, the TGA has reported no serious adverse events under the Authorized Prescriber scheme, and this clean safety record strongly supports program expansion and enhances public confidence in psychedelic treatments.
- Broadened Reimbursement: Coverage for psychedelic-assisted therapy now spans both public and private payers, including the Department of Veterans' Affairs and the National Disability Insurance Scheme, creating more employment opportunities for trained practitioners while expanding the patient base.
See More
Optimi Health Announces Nasdaq Uplisting and Public Offering
- Public Offering Pricing: Optimi Health Corp. has priced its public offering at $6.25 per share for 2.4 million shares, aiming to raise approximately $15 million, which will be utilized for scaling production and market expansion, reflecting the company's strong confidence in future growth.
- Nasdaq Trading Launch: The company's common shares are set to begin trading on the Nasdaq Capital Market under the symbol 'OPTH' on May 20, 2026, marking a significant milestone in its capital market journey, expected to enhance the company's visibility and investor confidence.
- Share Consolidation Effective: On May 19, 2026, Optimi completed a consolidation of shares at a ratio of 1 post-consolidation share for every 30 pre-consolidation shares, resulting in approximately 3.22 million shares outstanding, aimed at increasing per-share value and optimizing capital structure to enhance market competitiveness.
- Regulatory Compliance: The offering is conducted in compliance with the SEC's registration statement and will be available in all Canadian provinces except Quebec, ensuring the company's adherence to multiple market regulations and enhancing investor protection, thereby increasing trust among potential investors.
See More
Optimi Health Corp. Announces Nasdaq Uplisting and Public Offering
- Public Offering Pricing: Optimi Health Corp. is offering 2.4 million common shares at $6.25 each, with expected gross proceeds of approximately $15 million, which will support the company's market expansion and production scaling efforts.
- Underwriter Selection: Joseph Gunnar & Co., LLC has been appointed as the sole underwriter for the offering, indicating an increased trust in the company within capital markets and attracting attention from professional investors.
- Share Consolidation Effective: The company executed a consolidation of shares on May 19, 2026, at a ratio of 1 post-consolidation share for every 30 pre-consolidation shares, resulting in approximately 3,225,881 shares outstanding, aimed at enhancing share price and market appeal.
- Planned Use of Proceeds: The company intends to utilize the net proceeds for scaling production and distribution, market expansion, and general operating expenses, reflecting a proactive approach to future growth and strategic planning.
See More
Optimi Health Raises $15 Million in Share Offering
- Funding Achievement: Optimi Health successfully raised $15 million by offering 2.4 million shares at $6.25 each, slightly below the anticipated 2.5 million shares but still within the $6 to $8 pricing range, indicating market confidence in its products.
- Market Capitalization: Following this funding, Optimi Health's market cap is under $50 million, which will exclude it from Renaissance Capital's 2026 IPO statistics, potentially impacting its future financing and market perception.
- Business Background: As a licensed Canadian drug manufacturer, Optimi Health specializes in the production of MDMA and psilocybin, holding multiple licenses that allow it to manufacture, import, and distribute these controlled substances legally, ensuring compliance and competitiveness in the market.
- Exchange Listings: Optimi Health is currently listed on the Canadian Securities Exchange (OPTI) and the Frankfurt Stock Exchange (8BN), and will trade on Nasdaq under the symbol OPTH, further expanding its international market presence.
See More
Australia Broadens Eligibility for Psychedelic Therapy
- Expanded Therapist Eligibility: The TGA's updated framework broadens the eligibility for therapists in psychedelic-assisted therapy, which is expected to significantly enhance treatment capacity and meet the rising patient demand, thereby solidifying Australia's position as a leader in the global psychedelic market.
- Diverse Treatment Settings: The new regulations allow psychedelic therapy to be conducted in various medically supervised environments rather than solely in hospitals, which is anticipated to improve patient comfort and outcomes, further driving the commercialization of psychedelic treatments.
- Sustained Safety Profile: The TGA has confirmed that no serious adverse events have been reported under the Authorized Prescriber scheme since December 2025, and this clean safety record provides strong support for program expansion and enhances public confidence in psychedelic therapies.
- Expanded Reimbursement Coverage: Coverage for psychedelic-assisted therapy now spans both public and private payers, including the Department of Veterans' Affairs and the National Disability Insurance Scheme, creating more employment opportunities for trained practitioners while addressing the growing patient population.
See More
Australia Expands Eligibility for Psychedelic Therapy
- Expanded Therapist Eligibility: The TGA's updated framework broadens the eligibility for therapists in psychedelic-assisted therapy, which is expected to significantly enhance treatment capacity and meet the increasing patient demand, thereby solidifying Australia's leading position in the global psychedelic market.
- Diverse Treatment Settings: The new regulations allow psychedelic therapy to be conducted in various medically supervised environments, breaking the previous requirement for hospital settings, which is anticipated to improve patient comfort and treatment outcomes, promoting a wider range of therapeutic applications.
- Sustained Safety Profile: Since December 2025, the TGA has reported no serious adverse events, indicating a high safety profile for psychedelic treatments under regulated conditions, which provides strong support for further promotion and expansion of therapy programs.
- Expanded Reimbursement Coverage: The reimbursement for psychedelic therapy now spans both public and private payers, enhancing accessibility and affordability of treatments, which is expected to attract more trained practitioners into the market and drive growth in commercial supply.
See More
Australia Expands Eligibility for Psychedelic Therapy
- Expanded Therapist Eligibility: The TGA's updated framework broadens the eligibility for therapists in psychedelic-assisted therapy, particularly for MDMA and psilocybin, which is expected to significantly enhance treatment accessibility and meet the growing patient demand.
- Diverse Treatment Settings: The new regulations allow treatment to occur in various medically supervised environments rather than just inpatient settings, which is anticipated to improve patient comfort and outcomes, further promoting the adoption of psychedelic therapies.
- Continued Safety Profile: Since December 2025, the TGA has reported no serious adverse events under the Authorized Prescriber scheme, and this clean safety record strongly supports program expansion and enhances public confidence in psychedelic treatments.
- Broadened Reimbursement: Coverage for psychedelic-assisted therapy now spans both public and private payers, including the Department of Veterans' Affairs and the National Disability Insurance Scheme, creating more employment opportunities for trained practitioners while expanding the patient base.
See More
Optimi Health Announces Nasdaq Uplisting and Public Offering
- Public Offering Pricing: Optimi Health Corp. has priced its public offering at $6.25 per share for 2.4 million shares, aiming to raise approximately $15 million, which will be utilized for scaling production and market expansion, reflecting the company's strong confidence in future growth.
- Nasdaq Trading Launch: The company's common shares are set to begin trading on the Nasdaq Capital Market under the symbol 'OPTH' on May 20, 2026, marking a significant milestone in its capital market journey, expected to enhance the company's visibility and investor confidence.
- Share Consolidation Effective: On May 19, 2026, Optimi completed a consolidation of shares at a ratio of 1 post-consolidation share for every 30 pre-consolidation shares, resulting in approximately 3.22 million shares outstanding, aimed at increasing per-share value and optimizing capital structure to enhance market competitiveness.
- Regulatory Compliance: The offering is conducted in compliance with the SEC's registration statement and will be available in all Canadian provinces except Quebec, ensuring the company's adherence to multiple market regulations and enhancing investor protection, thereby increasing trust among potential investors.
See More
Optimi Health Corp. Announces Nasdaq Uplisting and Public Offering
- Public Offering Pricing: Optimi Health Corp. is offering 2.4 million common shares at $6.25 each, with expected gross proceeds of approximately $15 million, which will support the company's market expansion and production scaling efforts.
- Underwriter Selection: Joseph Gunnar & Co., LLC has been appointed as the sole underwriter for the offering, indicating an increased trust in the company within capital markets and attracting attention from professional investors.
- Share Consolidation Effective: The company executed a consolidation of shares on May 19, 2026, at a ratio of 1 post-consolidation share for every 30 pre-consolidation shares, resulting in approximately 3,225,881 shares outstanding, aimed at enhancing share price and market appeal.
- Planned Use of Proceeds: The company intends to utilize the net proceeds for scaling production and distribution, market expansion, and general operating expenses, reflecting a proactive approach to future growth and strategic planning.
See More
Optimi Health Raises $15 Million in Share Offering
- Funding Achievement: Optimi Health successfully raised $15 million by offering 2.4 million shares at $6.25 each, slightly below the anticipated 2.5 million shares but still within the $6 to $8 pricing range, indicating market confidence in its products.
- Market Capitalization: Following this funding, Optimi Health's market cap is under $50 million, which will exclude it from Renaissance Capital's 2026 IPO statistics, potentially impacting its future financing and market perception.
- Business Background: As a licensed Canadian drug manufacturer, Optimi Health specializes in the production of MDMA and psilocybin, holding multiple licenses that allow it to manufacture, import, and distribute these controlled substances legally, ensuring compliance and competitiveness in the market.
- Exchange Listings: Optimi Health is currently listed on the Canadian Securities Exchange (OPTI) and the Frankfurt Stock Exchange (8BN), and will trade on Nasdaq under the symbol OPTH, further expanding its international market presence.
See More
